BOULDER, Colo., Oct. 24, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2018 and hold a conference call to discuss those results on Tuesday, October 31, 2017. Ron Squarer, Chief Executive Officer, will lead the call.
Date: | Tuesday, October 31, 2017 |
Time: | 9:00 a.m. Eastern Time |
Toll-Free: | (844) 464-3927 |
Toll: | (765) 507-2598 |
Pass Code: | 94698561 |
Webcast, including Replay and Conference Call Slides:
https://edge.media-server.com/m6/p/hcxcet4b
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
CONTACT: | Tricia Haugeto |
Array BioPharma Inc. | |
(303) 386-1193 | |
View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-first-quarter-of-fiscal-2018-on-october-31-2017-300541497.html
SOURCE Array BioPharma Inc.
